Literature DB >> 18432811

Immunoenzymetric assay of mouse and human cytokines using NIP-labeled anti-cytokine antibodies.

J S Abrams1.   

Abstract

This unit describes a general method for immunoenzymetric assay of mouse and human cytokines. The technique is based on use of two anti-cytokine monoclonal antibodies (MAbs), each specific for a spatially distinct determinant on the cytokine. One of these is a coating antibody, and the other is a derivatized detecting antibody. A support protocol describes chemical labeling of anti-cytokine monoclonal IgG antibodies with the NIP hapten group to produce the detecting antibody. Another support protocol describes a method for producing horseradish peroxidase (HRPO)-conjugated J4, a rat IgG1 anti-NIP monoclonal antibody that confers the anti-NIP specificity to the HRPO detection system used in the immunoenzymetric assay. The method described in this unit has allowed successful measurement of different cytokines in a wide variety of clinical samples including conditioned medium, serum and plasma, ascites, amniotic fluid, and bronchoalveolar lavage fluid.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 18432811     DOI: 10.1002/0471142735.im0620s13

Source DB:  PubMed          Journal:  Curr Protoc Immunol        ISSN: 1934-3671


  3 in total

1.  Cytokine dysregulation in activated cystic fibrosis (CF) peripheral lymphocytes.

Authors:  R B Moss; Y P Hsu; L Olds
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

2.  Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice.

Authors:  S W Chensue; N W Lukacs; T Y Yang; X Shang; K A Frait; S L Kunkel; T Kung; M T Wiekowski; J A Hedrick; D N Cook; A Zingoni; S K Narula; A Zlotnik; F J Barrat; A O'Garra; M Napolitano; S A Lira
Journal:  J Exp Med       Date:  2001-03-05       Impact factor: 14.307

3.  Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide.

Authors:  A G Castro; M Neighbors; S D Hurst; F Zonin; R A Silva; E Murphy; Y J Liu; A O'Garra
Journal:  J Exp Med       Date:  2000-11-20       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.